|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MicroRNA-126 suppresses proliferation of undifferentiated (BRAF(V600E) and BRAF(WT)) thyroid carcinoma through targeting PIK3R2 gene and repressing PI3K-AKT proliferation-survival signalling pathway.
|
26384552 |
2015 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our aim was to determine the therapeutic efficacy of simultaneously targeting these pathways in thyroid cancer with a single agent and to evaluate biomarkers of treatment response.<b>Experimental Design:</b> CUDC-907 is a first-in-class compound, functioning as a dual inhibitor of HDACs and the PI3K/AKT pathway.
|
28600475 |
2017 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that miR-145 is a master regulator of thyroid cancer growth, mediates its effect through the PI3K/Akt pathway, is secreted by the thyroid cancer cells, and may serve as an adjunct biomarker for thyroid cancer diagnosis.
|
24781864 |
2014 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study demonstrates a genetic selectivity of MK2206 in inhibiting thyroid cancer cells by targeting the PI3K/Akt pathway, supporting a clinical trial in thyroid cancer.
|
21289267 |
2011 |
|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent novel and promising findings include additional abnormalities in key pathways associated with thyroid tumorigenesis (RET-Ras-BRAF-MEK; RET-beta-cateinin; TRK-PI3K-AKT; and MDM-p53-PTEN), single-nucleotide polymorphisms associated with thyroid cancer susceptibility, epigenetic silencing, alternative splicing, and gene expression abnormalities.
|
19907326 |
2010 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest that EDAG-1 regulates the proliferation and apoptosis of thyroid carcinoma via the PI3K/Akt signaling pathway.
|
27261581 |
2016 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PI3K/Akt pathway may thus be a major therapeutic target in thyroid cancers.
|
17317825 |
2007 |
|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The initiation of thyroid cancer is often triggered by a genetic mutation in the phosphortidylinositol-3 kinase (PI3K) or mitogen-activated protein kinase (MAPK) pathway, such as <i>RAS</i> and <i>BRAF</i>, or by the rearrangement of growth factor receptor tyrosine kinase genes such as <i>RET/PTC</i>.
|
29163356 |
2017 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present review focuses on the most recent developments on the role of the PI3K/Akt pathway in the pathogenesis of non-medullary TC and will provide insight into how this pathway can be targeted either alone or in the context of multimodal therapeutic strategies for treatment of advanced TC.
|
26138515 |
2015 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These distinct genetic alterations constitutively activate the MAPK, PI3K and β-catenin signaling pathways, which have been implicated in thyroid cancer development and progression.
|
23128507 |
2013 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings may add to the concept of targeting the PI3K pathway in advanced thyroid cancers.
|
27258970 |
2016 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This genotype-based targeting of the PI3K/Akt pathway using Akt and mTOR inhibitors may offer an effective therapeutic strategy for thyroid cancer and warrants further studies.
|
19706758 |
2009 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, combined PI3K/mTOR and CDK4/6 inhibition is a highly promising novel approach for the treatment of aggressive, therapy-resistant thyroid cancer.
|
30699064 |
2019 |
|
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We recently showed that autocrine production of interleukin (IL)-4 and IL-10 controls thyroid cancer cell survival, growth, and resistance to chemotherapy through activation of Janus-activated kinase/signal transducers and activators of transcription (JAK/STAT) and phosphatidylinositide 3'-OH kinase (PI3K)/Akt pathways.
|
17545635 |
2007 |